News Articles

04/22/2019

SeraCare to Develop NGS Standards for Tumor Mutational Burden Monitoring

SeraCare Life Sciences, Milford, Mass, a provider of quality control materials for the infectious disease testing and next-generation sequencing (NGS) markets, has been selected as a technology partner in support of the first-ever external quality assessment program for tumor mutational burden monitoring, which is being developed by the International Quality Network for Pathology (IQN Path).

04/12/2019

Making the Shift from Technological Innovation to Operational Excellence: Delivering on the Promise of Next-Generation Sequencing for Personalized Medicine

Targeted therapies and now recently, immunotherapies, have demonstrated great promise towards increasing response rates, as well as duration of response for cancer patients. This is often achieved by understanding biomarkers associated with therapeutic response and then stratifying patients accordingly. In many cases, this is accomplished through the application of companion diagnostics which have been developed using various approaches including immunohistochemistry, polymerase chain reaction (PCR), and more recently, next‑generation sequencing (NGS).

02/28/2019

Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer

Lung cancer accounts for approximately 14% of all newly diagnosed cancers and is the leading cause of cancer-related deaths. Chimeric RNA resulting from gene fusions (RNA fusions) and other RNA splicing errors are driver events and clinically addressable targets for non–small cell lung cancer (NSCLC).

01/24/2019

SeraCare partners with AccuRef, Bayer

SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products.

12/10/2018

SeraCare Acquired by LGC

Manufacturer of quality control materials SeraCare Life Sciences has been acquired by LGC, an international life sciences measurement and testing company, strengthening LGC’s position in the clinical quality control tools market.

11/05/2018

SeraCare NTRK Reference Material Panel

SeraCare Life Sciences has announced the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion material panel developed in partnership with Bayer.

06/07/2018

New ctDNA reference materials for NGS

SeraCare Life Sciences is adding ct­DNA Complete and ctDNA Panels to its circulating tumor DNA portfolio of reference materials. These new materials expand the Seraseq product line to also cover copy number variations and accelerate single-gene and variant-focused testing.

01/08/2018

SeraCare Life Sciences Announces Joe Bernardo as New Company Chairman

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced that Joe Bernardo has joined SeraCare’s board of directors in the role of Chairman. Mr. Bernardo is also an Operating Partner at Linden Capital Partners who are the equity investors behind SeraCare Life Sciences.